跳至主要内容
临床试验/NCT04957875
NCT04957875已完成不适用

Timing of Endoscopy for Acute Variceal Bleeding in Patients With Cirrhosis (CHESS1905): a Nationwide Cohort Study

Hepatopancreatobiliary Surgery Institute of Gansu Province1 个研究点 分布在 1 个国家目标入组 3,300 人开始时间: 2019年12月16日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
3,300
试验地点
1
主要终点
the incidence of 5-day rebleeding after emergency endoscopy

研究概览

简要总结

Cirrhotic patients with AVB across 34 university medical centers in 30 cities in China from February 2013 to May 2020 who underwent endoscopy within 24 hours were included in this study. Patients were divided into an urgent endoscopy group (endoscopy <6h after admission) and an early endoscopy group (endoscopy 6-24h after admission). Outcomes included the incidence of 5-day rebleeding, in-hospital mortality, need for intensive care unit (ICU) and the length of hospital stay after the endoscopy management. Multivariable analysis was performed to identify risk factors for rebleeding. A propensity score matching (PSM) analysis was performed to achieve a balance at baseline between the urgent and early groups.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • established diagnosis of cirrhosis (based on liver biopsy or the combination of clinical, biochemical, and imaging findings)
  • witnessed or reported evidence of gastrointestinal haemorrhage (hematemesis, melenemesis, or hematochezia)
  • esophageal or gastric varices confirmed endoscopically as the source of bleeding

排除标准

  • severe dysfunction of a major extrahepatic organ (e.g., heart failure, pulmonary disease, and terminal malignancy except hepatocellular carcinoma)
  • history of endoscopic therapy for varices (ligation or sclerotherapy) within three months
  • incomplete or missing data

结局指标

主要结局

the incidence of 5-day rebleeding after emergency endoscopy

时间窗: 6 months

次要结局

  • need for ICU(6 months)
  • the length of hospital stay(6 months)
  • the in-hospital mortality(6 months)

研究者

发起方
Hepatopancreatobiliary Surgery Institute of Gansu Province
申办方类型
Other
责任方
Principal Investigator
主要研究者

Xiaolong Qi

Chief, Institute of Portal Hypertension, The First Hospital of Lanzhou University

Hepatopancreatobiliary Surgery Institute of Gansu Province

研究点 (1)

Loading locations...

相似试验